1 – 5 of 10
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
(
- Contribution to journal › Article
- 2022
-
Mark
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
(
- Contribution to journal › Article
- 2021
-
Mark
Pharmacological modulation of T cell immunity results in long-term remission of autoimmune arthritis
(
- Contribution to journal › Article
- 2015
-
Mark
Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
(
- Contribution to journal › Article
-
Mark
Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
(
- Contribution to journal › Article